Key result
Medical therapies fail to reduce AAA growth or mortality, while propranolol and ticagrelor increase adverse discontinuations.
Why the study?
Many medical therapies have been assessed for reducing subthreshold abdominal aortic aneurysm expansion, but evidence remains inconclusive.
Do medical therapies reduce AAA growth rate and mortality in patients with subthreshold abdominal aortic aneurysms?
Comparison
Various medical treatments vs placebo
Design
Network meta-analysis of randomized controlled trials
Authors
Loading...
Surveillance alone remains standard for subthreshold AAA; reinforces lack of effective pharmacological options and leaves open need for novel agents.
Do medical therapies reduce AAA growth rate and mortality in patients with subthreshold abdominal aortic aneurysms?
Current medical therapies do not significantly reduce subthreshold AAA growth, surgery referral, or mortality compared to placebo, highlighting the lack of proven pharmacological treatments to halt AAA progression.
Lu et al. (2026) studied this question. Medical therapies did not reduce subthreshold abdominal aortic aneurysm growth or mortality, while propranolol (OR 3.14) and ticagrelor (OR 5.10) increased adverse event discontinuations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: